Sarah C. Garrett-Thomson

Sarah C. Garrett-Thomson

Auto-generated profile, based on publicly available information

Sarah C. Garrett-Thomson

Albert Einstein College of Medicine, Bronx, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 December 2021 in Nature Reviews Drug Discovery
Verified
Journal Article
Closed access
PDF file
AKAlan J. Korman
Alan J. Korman
SGSarah C. Garrett-Thomson
Sarah C. Garrett-Thomson
NLNils Lonberg
Nils Lonberg

27 March 2019 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
ESEric L. Smith
Eric L. Smith
KHKim Harrington
Kim Harrington
MSMette Staehr
Mette Staehr
RMReed Masakayan
Reed Masakayan
JJJon Jones
Jon Jones
RBRenier J. Brentjens
Renier J. Brentjens
Early clinical results of chimeric antigen receptor (CAR) T cell therapy targeting B cell maturation antigen (BCMA) for multiple myeloma (MM) appear promising, but relapses associated with residual low-to-negative BCMA-expressing MM cells have been reported, necessitating identification of additional targets. The orphan G protein–coupled receptor, class C group 5 member D (GPRC5D), normally expressed only in the hair follicle, was previously identified as expressed by mRNA in marrow aspirates from patients with MM, but confirmation of protein expression remained elusive. Using quantitative immunofluorescence, we determined that GPRC5D protein is expressed on CD138+ MM cells from primary marrow samples with a distribution that was similar to, but independent of, BCMA. Panning a human B cell–derived phage display library identified seven GPRC5D-specific single-chain variable fragments (scFvs). Incorporation of these into multiple CAR formats yielded 42 different constructs, which were screened for antigen-specific and antigen-independent (tonic) signaling using a Nur77-based reporter system. Nur77 reporter screen results were confirmed in vivo using a marrow-tropic MM xenograft in mice. CAR T cells incorporating GPRC5D-targeted scFv clone 109 eradicated MM and enabled long-term survival, including in a BCMA antigen escape model. GPRC5D(109) is specific for GPRC5D and resulted in MM cell line and primary MM cytotoxicity, cytokine release, and in vivo activity comparable to anti-BCMA CAR T cells. Murine and cynomolgus cross-reactive CAR T cells did not cause alopecia or other signs of GPRC5D-mediated toxicity in these species. Thus, GPRC5D(109) CAR T cell therapy shows potential for the treatment of advanced MM irrespective of previous BCMA-targeted therapy.

4 June 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SGSarah C Garrett-Thomson
Sarah C Garrett-Thomson
AMAldo Massimi
Aldo Massimi
EFElena V Fedorov
Elena V Fedorov
JBJeffrey B Bonanno
Jeffrey B Bonanno
LSLisa Scandiuzzi
Lisa Scandiuzzi
SASteven C Almo
Steven C Almo
The B7 family represents one of the best-studied subgroups within the Ig superfamily, yet new interactions continue to be discovered. However, this binding promiscuity represents a major challenge for defining the biological contribution of each specific interaction. We developed a strategy for addressing these challenges by combining cell microarray and high-throughput FACS methods to screen for promiscuous binding events, map binding interfaces, and generate functionally selective reagents. Applying this approach to the interactions of mPD-L1 with its receptor mPD-1 and its ligand mB7-1, we identified the binding interface of mB7-1 on mPD-L1 and as a result generated mPD-L1 mutants with binding selectivity for mB7-1 or mPD-1. Next, using a panel of mB7-1 mutants, we mapped the binding sites of mCTLA-4, mCD28 and mPD-L1. Surprisingly, the mPD-L1 binding site mapped to the dimer interface surface of mB7-1, placing it distal from the CTLA-4/CD28 recognition surface. Using two independent approaches, we demonstrated that mPD-L1 and mB7-1 bind in cis, consistent with recent reports from Chaudhri A et al. and Sugiura D et al. We further provide evidence that while CTLA-4 and CD28 do not directly compete with PD-L1 for binding to B7-1, they can disrupt the cis PD-L1:B7-1 complex by reorganizing B7-1 on the cell surface. These observations offer new functional insights into the regulatory mechanisms associated with this group of B7 family proteins and provide new tools to elucidate their function in vitro and in vivo.

28 October 2021 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
WLWeifeng Liu
Weifeng Liu
TCTing-Fang Chou
Ting-Fang Chou
SGSarah C. Garrett-Thomson
Sarah C. Garrett-Thomson
GSGoo-Young Seo
Goo-Young Seo
EFElena Fedorov
Elena Fedorov
SASteven C Almo
Steven C Almo
HVEM is a TNF (tumor necrosis factor) receptor contributing to a broad range of immune functions involving diverse cell types. It interacts with a TNF ligand, LIGHT, and immunoglobulin (Ig) superfamily members BTLA and CD160. Assessing the functional impact of HVEM binding to specific ligands in different settings has been complicated by the multiple interactions of HVEM and HVEM binding partners. To dissect the molecular basis for multiple functions, we determined crystal structures that reveal the distinct HVEM surfaces that engage LIGHT or BTLA/CD160, including the human HVEM–LIGHT–CD160 ternary complex, with HVEM interacting simultaneously with both binding partners. Based on these structures, we generated mouse HVEM mutants that selectively recognized either the TNF or Ig ligands in vitro. Knockin mice expressing these muteins maintain expression of all the proteins in the HVEM network, yet they demonstrate selective functions for LIGHT in the clearance of bacteria in the intestine and for the Ig ligands in the amelioration of liver inflammation.

14 January 2022 in Nature Reviews Drug Discovery
Verified
Journal Article
Closed access
PDF file
AKAlan J. Korman
Alan J. Korman
SGSarah C. Garrett-Thomson
Sarah C. Garrett-Thomson
NLNils Lonberg
Nils Lonberg